A recent multi-gene 3p analysis conducted in a preclinical study on cell line and cell culture in mice suggests a possible negative predictive effect of SETD2 alterations for ICI-based regimens, whereas pan-cancer work links SETD2 mutation to a more “inflamed” phenotype. The gene discussed is SETD2; the disease is cancer.